Multiple endocrine neoplasia type 2
(Redirected from MEN 2A)
Multiple endocrine neoplasia type 2 (MEN2) is a hereditary condition associated with tumors of the endocrine (hormone producing) glands. It is characterized by the occurrence of medullary thyroid carcinoma, pheochromocytoma, and parathyroid adenoma or hyperplasia. There are three subtypes of MEN2, namely MEN2A, MEN2B, and Familial Medullary Thyroid Carcinoma (FMTC).
Genetics[edit | edit source]
MEN2 is an autosomal dominant disorder, which means that it can be passed on to offspring by just one affected parent. It is caused by mutations in the RET proto-oncogene on chromosome 10. The RET gene provides instructions for producing a protein that is involved in signaling within cells, which can trigger cell division and maturation.
Subtypes[edit | edit source]
MEN2A[edit | edit source]
MEN2A is the most common subtype, accounting for about 70-80% of all MEN2 cases. It is characterized by medullary thyroid carcinoma, pheochromocytoma, and parathyroid adenoma or hyperplasia.
MEN2B[edit | edit source]
MEN2B is less common and more aggressive than MEN2A. It is characterized by medullary thyroid carcinoma, pheochromocytoma, and multiple mucosal neuromas. Unlike MEN2A, parathyroid disease is not typically seen in MEN2B.
Familial Medullary Thyroid Carcinoma (FMTC)[edit | edit source]
FMTC is the least common subtype of MEN2. It is characterized by medullary thyroid carcinoma only, without the other features of MEN2A or MEN2B.
Diagnosis[edit | edit source]
Diagnosis of MEN2 is based on clinical findings and genetic testing. Genetic testing can identify mutations in the RET gene that cause MEN2. It is recommended for individuals with a family history of MEN2 or related conditions.
Treatment[edit | edit source]
Treatment for MEN2 depends on the specific features of the condition in each individual. It may include surgery, medication, and regular monitoring.
See also[edit | edit source]
References[edit | edit source]
| Multiple endocrine neoplasia type 2 Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
